CYTEIR THERAPEUTICS
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
CYTEIR THERAPEUTICS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2012-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cyteir.com
Total Employee:
11+
Status:
Active
Contact:
312-953-3651
Email Addresses:
[email protected]
Total Funding:
156.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Wordpress Plugins
Similar Organizations
7 Hills Pharma
7 Hills Pharma is developing novel immunotherapies for the treatment Of cancer.
Ankyra
Ankyra is developing a platform to significantly improve both the safety and efficacy of cytokine immunotherapies for cancer.
Avro
Avro Life Science is developing skin patches for generic drug delivery, focusing on therapeutics for children and the elderly.
Brise Pharma
Brise Pharma operates in the scientific research and technical service industry.
Cadence Health
Cadence, a pharma startup, aims to switch a birth control pill over-the-counter to create easy and affordable access to contraceptives.
CaroGen
CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
Cartesian Therapeutics
Pioneering Potent, Safer Cell Therapy in and Beyond Oncology
EIP Pharma
EIP Pharma Provides Healthcare Services.
EpiVario
EpiVario develops novel compounds to treat memory-related psychiatric disorders at the source of the disease.
F-Star Therapeutics
F-Star Therapeutics is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology.
FTEX
FTEX Develops next-generation GaNFET based Electric Vehicle (EV) powertrains that extend the range and power of EVs by up to 30%.
HDT Bio
IMMUNE THERAPY FOR ALL: We’re transforming inventive immunotherapies for oncology and infectious disease.
HQS Quantum Simulations
HQS Quantum Simulations is developing quantum algorithms to predict molecular properties for specialty chemicals & pharmaceutical companies.
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Innoviva
Innoviva is committed to building long-lasting value and improving patient care.
Intabio
Intabio is a developer of a real-time protein analytics platform used to transform the development of biotherapeutic drug.
JOINN Biologics
Your premier CDMO for biologics drug development and manufacturing, from early development, to IND, to commercial stage.
LB Pharmaceuticals
LB Pharmaceuticals specializes in developing a treatment for schizophrenia.
Mana Therapeutics
Next-Generation Immunotherapies
MyMeds&Me
My Meds & Me provides a web-based solution for the capture of adverse event, product complaint.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
Nivagen Pharmaceuticals, Inc.
Nivagen engages in the development, acquisition, and sales of generic prescription drugs and over the counter products.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
PanCryos
PanCryos develops a next generation stem cell derived allogenic cell therapy or Type 1 diabetes.
Galectin Therapeutics
Galectin Therapeutics uses galectin science and drug development to create new therapies for fibrotic diseases and cancer.
Recludix Pharma
Recludix pharma is a developing platform to treat cancer patients.
RUTI Immune
RUTI Immune developing a vaccine against Covid-19 and other known or unknown viruses.
Sisu Pharma
Sisu Pharma is developing drugs against a new target to treat prostate cancer.
T-knife
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Vibliome
Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
XellSmart
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
CaaS Capital Management
CaaS Capital Management investment in Series C - Cyteir Therapeutics
Venrock
Venrock investment in Series C - Cyteir Therapeutics
Droia Ventures
Droia Ventures investment in Series C - Cyteir Therapeutics
Ample Plus Fund
Ample Plus Fund investment in Series C - Cyteir Therapeutics
Ally Bridge Group
Ally Bridge Group investment in Series C - Cyteir Therapeutics
Lightstone Ventures
Lightstone Ventures investment in Series C - Cyteir Therapeutics
Avidity Partners
Avidity Partners investment in Series C - Cyteir Therapeutics
Acuta Capital Partners
Acuta Capital Partners investment in Series C - Cyteir Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Cyteir Therapeutics
Novo Holdings
Novo Holdings investment in Series C - Cyteir Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-03 | Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality |
Official Site Inspections
http://www.cyteir.com Semrush global rank: 5.15 M Semrush visits lastest month: 1.57 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
